Plandai Biotechnology Inc Financials
This page shows Plandai Biotechnology Inc (PLPL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2015 annual data. Scores normalized against common benchmarks. How we calculate these scores
Plandai Biotechnology Inc has an operating margin of -9526.1%, meaning the company retains $-9526 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -2992.9% the prior year.
Plandai Biotechnology Inc's revenue declined 65% year-over-year, from $266K to $93K. This contraction results in a growth score of 0/100.
Plandai Biotechnology Inc's current ratio of 0.03 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 0/100, which could limit financial flexibility.
While Plandai Biotechnology Inc generated -$2.7M in operating cash flow, capex of $857K consumed most of it, leaving -$3.6M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Plandai Biotechnology Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Plandai Biotechnology Inc generates $0.27 in operating cash flow (-$2.7M OCF vs -$10.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Plandai Biotechnology Inc earns $-9.5 in operating income for every $1 of interest expense (-$8.8M vs $929K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Plandai Biotechnology Inc generated $93K in revenue in fiscal year 2015. This represents a decrease of 65.0% from the prior year.
Plandai Biotechnology Inc's EBITDA was -$8.4M in fiscal year 2015, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 8.6% from the prior year.
Plandai Biotechnology Inc generated -$3.6M in free cash flow in fiscal year 2015, representing cash available after capex. This represents an increase of 4.1% from the prior year.
Plandai Biotechnology Inc reported -$10.1M in net income in fiscal year 2015. This represents an increase of 37.2% from the prior year.
Plandai Biotechnology Inc held $34K in cash against $0 in long-term debt as of fiscal year 2015.
Plandai Biotechnology Inc had 161M shares outstanding in fiscal year 2015. This represents an increase of 22.5% from the prior year.
Plandai Biotechnology Inc's operating margin was -9526.1% in fiscal year 2015, reflecting core business profitability. This is down 6533.3 percentage points from the prior year.
Plandai Biotechnology Inc's net profit margin was -10842.4% in fiscal year 2015, showing the share of revenue converted to profit. This is down 4803.9 percentage points from the prior year.
Plandai Biotechnology Inc invested $857K in capex in fiscal year 2015, funding long-term assets and infrastructure. This represents a decrease of 23.5% from the prior year.
PLPL Income Statement
| Metric | Q3'16 | Q2'16 | Q1'16 | Q3'15 | Q3'15 | Q2'15 | Q1'15 | Q3'14 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $100K+98.4% | $51K+23.8% | $41K | N/A | $22K-67.6% | $67K+154.3% | $26K+102.1% | $13K |
| Cost of Revenue | N/A | N/A | N/A | N/A | $181K-15.9% | $216K+34.7% | $160K-35.4% | $248K |
| Gross Profit | N/A | N/A | N/A | N/A | -$159K-7.4% | -$148K-11.1% | -$134K+43.0% | -$235K |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $193K+103.2% | $95K-22.9% | $123K | N/A | $515K+17.1% | $440K-30.9% | $636K-32.9% | $947K |
| Operating Income | -$725K-3.7% | -$699K+20.5% | -$879K | N/A | -$6.0M-416.8% | -$1.2M+21.4% | -$1.5M+55.2% | -$3.3M |
| Interest Expense | $375K+15.9% | $324K+4.5% | $310K | N/A | $296K+121.2% | $134K+13.6% | $118K-26.2% | $160K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$1.1M-45.9% | -$750K+36.9% | -$1.2M | N/A | -$6.3M-385.2% | -$1.3M-111.6% | -$611K+93.1% | -$8.9M |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PLPL Balance Sheet
| Metric | Q3'16 | Q2'16 | Q1'16 | Q3'15 | Q3'15 | Q2'15 | Q1'15 | Q3'14 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.6M+4.0% | $6.4M-11.7% | $7.2M-15.1% | $8.5M-14.1% | $9.9M-9.2% | $10.9M-0.5% | $10.9M+13.0% | $9.7M |
| Current Assets | $176K+1.6% | $174K+21.7% | $143K-65.9% | $418K+52.9% | $273K-76.0% | $1.1M-34.0% | $1.7M+191.2% | $594K |
| Cash & Equivalents | $8K-41.0% | $14K+142.9% | $6K-83.5% | $34K-73.7% | $128K-86.3% | $931K-36.9% | $1.5M+842.9% | $157K |
| Inventory | $54K+18.7% | $45K+631.2% | $6K+172.1% | $2K-34.8% | $4K+10.6% | $3K+43.8% | $2K-12.6% | $3K |
| Accounts Receivable | $48K+155.4% | $19K+26.0% | $15K-12.9% | $17K+143.4% | $7K-39.0% | $12K-6.0% | $12K+50.9% | $8K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $15.0M+8.3% | $13.9M-4.0% | $14.4M-14.2% | $16.8M+7.1% | $15.7M+0.1% | $15.7M+7.2% | $14.6M+10.7% | $13.2M |
| Current Liabilities | $15.4M+7.4% | $14.4M-2.9% | $14.8M-2.3% | $15.1M+81.1% | $8.4M+8.8% | $7.7M+2558.7% | $289K+27.4% | $227K |
| Long-Term Debt | N/A | N/A | N/A | N/A | $5.7M-13.5% | $6.6M-49.4% | $13.0M+11.4% | $11.6M |
| Total Equity | -$8.4M-11.9% | -$7.5M-3.7% | -$7.2M-11.0% | -$6.5M-51.8% | -$4.3M-26.2% | -$3.4M-42.4% | -$2.4M-8.1% | -$2.2M |
| Retained Earnings | -$39.3M-2.8% | -$38.2M-2.0% | -$37.5M-3.3% | -$36.3M-7.1% | -$33.9M-22.2% | -$27.8M-4.3% | -$26.6M-2.5% | -$26.0M |
PLPL Cash Flow Statement
| Metric | Q3'16 | Q2'16 | Q1'16 | Q3'15 | Q3'15 | Q2'15 | Q1'15 | Q3'14 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$391K-161.4% | -$150K+48.2% | -$288K+81.8% | -$1.6M-168.0% | -$593K-11.7% | -$530K-7383.4% | $7K+101.0% | -$760K |
| Capital Expenditures | $2K-50.2% | $4K-35.1% | $6K-94.5% | $105K+215.2% | -$91K-112.3% | $739K+608.1% | $104K+1233.1% | $8K |
| Free Cash Flow | -$393K-156.2% | -$153K+47.9% | -$294K+82.6% | -$1.7M-147.6% | -$684K+46.1% | -$1.3M-1207.8% | -$97K+87.4% | -$768K |
| Investing Cash Flow | -$2K+50.2% | -$4K+35.1% | -$6K+94.5% | -$105K-215.2% | $91K+112.3% | -$739K-608.1% | -$104K-1252.1% | -$8K |
| Financing Cash Flow | $390K+129.4% | $170K-44.4% | $305K-82.6% | $1.8M+636.7% | -$328K-150.4% | $650K-66.7% | $2.0M+553.8% | $299K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
PLPL Financial Ratios
| Metric | Q3'16 | Q2'16 | Q1'16 | Q3'15 | Q3'15 | Q2'15 | Q1'15 | Q3'14 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | -733.4%-512.1pp | -221.3%+285.3pp | -506.6%+1290.1pp | -1796.6% |
| Operating Margin | -722.8%+659.5pp | -1382.3%+770.9pp | -2153.2% | N/A | -27544.4%-25817.3pp | -1727.1%+3860.2pp | -5587.3%+19605.8pp | -25193.0% |
| Net Margin | -1091.6%+392.5pp | -1484.1%+1428.0pp | -2912.1% | N/A | -28848.3%-26921.7pp | -1926.7%+388.7pp | -2315.4%+66003.9pp | -68319.3% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -16.5%-4.7pp | -11.8%+4.7pp | -16.5% | N/A | -63.4%-51.5pp | -11.9%-6.3pp | -5.6%+86.5pp | -92.1% |
| Current Ratio | 0.010.0 | 0.010.0 | 0.01-0.0 | 0.030.0 | 0.03-0.1 | 0.15-5.8 | 5.98+3.4 | 2.62 |
| Debt-to-Equity | -1.79+0.1 | -1.85+0.1 | -2.00+0.6 | -2.59-1.3 | -1.32+0.6 | -1.93+3.5 | -5.44-0.2 | -5.28 |
| FCF Margin | -391.5%-88.3pp | -303.2%+417.5pp | -720.6% | N/A | -3144.1%-1252.6pp | -1891.5%-1523.7pp | -367.8%+5517.6pp | -5885.3% |
Note: Shareholder equity is negative (-$6.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Plandai Biotechnology Inc's annual revenue?
Plandai Biotechnology Inc (PLPL) reported $93K in total revenue for fiscal year 2015. This represents a -65.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Plandai Biotechnology Inc's revenue growing?
Plandai Biotechnology Inc (PLPL) revenue declined by 65% year-over-year, from $266K to $93K in fiscal year 2015.
Is Plandai Biotechnology Inc profitable?
No, Plandai Biotechnology Inc (PLPL) reported a net income of -$10.1M in fiscal year 2015, with a net profit margin of -10842.4%.
What is Plandai Biotechnology Inc's EBITDA?
Plandai Biotechnology Inc (PLPL) had EBITDA of -$8.4M in fiscal year 2015, measuring earnings before interest, taxes, depreciation, and amortization.
What is Plandai Biotechnology Inc's operating margin?
Plandai Biotechnology Inc (PLPL) had an operating margin of -9526.1% in fiscal year 2015, reflecting the profitability of core business operations before interest and taxes.
What is Plandai Biotechnology Inc's net profit margin?
Plandai Biotechnology Inc (PLPL) had a net profit margin of -10842.4% in fiscal year 2015, representing the share of revenue converted into profit after all expenses.
What is Plandai Biotechnology Inc's free cash flow?
Plandai Biotechnology Inc (PLPL) generated -$3.6M in free cash flow during fiscal year 2015. This represents a 4.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Plandai Biotechnology Inc's operating cash flow?
Plandai Biotechnology Inc (PLPL) generated -$2.7M in operating cash flow during fiscal year 2015, representing cash generated from core business activities.
What are Plandai Biotechnology Inc's total assets?
Plandai Biotechnology Inc (PLPL) had $8.5M in total assets as of fiscal year 2015, including both current and long-term assets.
What are Plandai Biotechnology Inc's capital expenditures?
Plandai Biotechnology Inc (PLPL) invested $857K in capital expenditures during fiscal year 2015, funding long-term assets and infrastructure.
How many shares does Plandai Biotechnology Inc have outstanding?
Plandai Biotechnology Inc (PLPL) had 161M shares outstanding as of fiscal year 2015.
What is Plandai Biotechnology Inc's current ratio?
Plandai Biotechnology Inc (PLPL) had a current ratio of 0.03 as of fiscal year 2015, which is below 1.0, which may suggest potential liquidity concerns.
What is Plandai Biotechnology Inc's debt-to-equity ratio?
Plandai Biotechnology Inc (PLPL) had a debt-to-equity ratio of -2.59 as of fiscal year 2015, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Plandai Biotechnology Inc's return on assets (ROA)?
Plandai Biotechnology Inc (PLPL) had a return on assets of -118.4% for fiscal year 2015, measuring how efficiently the company uses its assets to generate profit.
What is Plandai Biotechnology Inc's cash runway?
Based on fiscal year 2015 data, Plandai Biotechnology Inc (PLPL) had $34K in cash against an annual operating cash burn of $2.7M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Plandai Biotechnology Inc's debt-to-equity ratio negative or unusual?
Plandai Biotechnology Inc (PLPL) has negative shareholder equity of -$6.5M as of fiscal year 2015, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Plandai Biotechnology Inc's Piotroski F-Score?
Plandai Biotechnology Inc (PLPL) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Plandai Biotechnology Inc's earnings high quality?
Plandai Biotechnology Inc (PLPL) has an earnings quality ratio of 0.27x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Plandai Biotechnology Inc cover its interest payments?
Plandai Biotechnology Inc (PLPL) has an interest coverage ratio of -9.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Plandai Biotechnology Inc?
Plandai Biotechnology Inc (PLPL) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.